Skip to main content
Delfa

← Trials/Trial dossier/NCT00211224

TerminatedPhase 3

Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)

Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)

Asset

Riluzole

Listed sites

1

Recruiting sites

-

Enrollment

800

Study population

Frontotemporal dementia

Key I/E criterion

•Age 30-80

Primary endpoint

•Survival

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

SecondaryEuropean Commission
NCT IDNCT00211224
Org study IDQLG1-2000-01262
SecondaryQLG1-2000-01262

Timeline

Milestones

Study start2000-04 (month precision)
Study completion2004-11 (month precision)
Study first posted2005-09-21estimated
Last update posted2005-12-15estimated

Assets

Drug assets

Riluzole

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age30 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•akinetic rigid syndrome plus clinical criteria for MSA or PSP

Exclusion criteria

•Idiopathic Parkinson's disease
•Other neurological or serious medical disorders
•Unable to give informed consent
•dementia
•liver damage
•women of child bearing age unable to use effective method of contraception

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Neuroimaging
1
Other clinical outcomes
1

Neuroimaging

1 endpoint
Secondary/protocol endpoint

Change in MRI abnormalities

change from baseline, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

survival

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

functional measures (UPDRS, Parkinson's Plus Scale)

descriptive

Secondary/protocol endpoint/low confidence

Cognitive changes

descriptive

Publications (4)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.